Patents by Inventor Matthias Degenhardt

Matthias Degenhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20070077307
    Abstract: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.
    Type: Application
    Filed: June 7, 2006
    Publication date: April 5, 2007
    Inventors: Joerg Rosenberg, Katja Fastnacht, Matthias Degenhardt, Joerg Breitenbach, Kennan Marsh, Rajeev Garg
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20070048384
    Abstract: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.
    Type: Application
    Filed: June 7, 2006
    Publication date: March 1, 2007
    Inventors: Joerg Rosenberg, Katja Fastnacht, Matthias Degenhardt, Joerg Breitenbach, Kennan Marsh, Rajeev Garg
  • Pharmaceutical compositions
    Publication number: 20070049636
    Abstract: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.
    Type: Application
    Filed: December 2, 2005
    Publication date: March 1, 2007
    Inventors: Joerg Rosenberg, Katja Fastnacht, Matthias Degenhardt, Joerg Breitenbach, Kennan Marsh, Rajeev Garg
  • Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
    Publication number: 20060134196
    Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.
    Type: Application
    Filed: December 16, 2003
    Publication date: June 22, 2006
    Applicant: ABBOTT GmbH & Co. KG
    Inventors: Joerg Rosenberg, Matthias Degenhardt, Joerg Breitenbach, Tom Reiland, Kennan Marsh